# US 2025/0145945 A1 · Culture media for culturing pluripotent stem cells in suspension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145945 A1
- Document ID: US20250145945A1
- Status: Published application
- Kind: A1
- Application number: 19/012,564
- Filed: 2025-01-07
- Published: 2025-05-08
- Earliest claimed: 2016-07-19
- Assignees: Accellta Ltd.
- Applicants: Accellta Ltd.
- Inventors: Michal AMIT; Itzchak ANGEL
- Web page: https://patentgrep.com/patent/US20250145945A1

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C07K 14/81: Protease inhibitors
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0031: {Serum-free culture media}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2500/99: Serum-free medium
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are defined culture media for culturing pluripotent stem cells in a suspension culture devoid of substrate adherence, the defined culture media comprising an effective amount of a protease inhibitor; a GSK3β inhibitor and at least one agent selected from the group consisting of a protease inhibitor and a WNT3A polypeptide; a WNT3A polypeptide and a stabilizing agent thereof with the proviso that said stabilizing agent is not a lipid vesicle; and/or a GSK3β inhibitor, with the proviso that the medium is devoid of an ERK1/2 inhibitor. Also provided are cell cultures and methods of suing same.

## Claims

### Claim 1

A defined culture medium comprising an effective amount of a protease inhibitor and at least one of a defined lipid mixture or a serum replacement, wherein said protease inhibitor is Tosyl-L-lysyl-chloromethane hydrochloride (TLCK) being present in said defined culture medium in a concentration that inhibits degradation of a WNT3 polypeptide, wherein the culture medium is capable of maintaining human pluripotent stem cells in a pluripotent state when cultured in a suspension culture devoid of substrate adherence, for at least 2 passages.

### Claim 2 (depends on 1)

The defined culture medium of claim 1, wherein said TLCK is present in said defined culture medium in a concentration range of 20 μM to 80 μM.

### Claim 3 (depends on 1)

The defined culture medium of claim 1, further comprising a GSK3β inhibitor.

### Claim 4 (depends on 1)

The defined culture medium of claim 1, further comprising a WNT3A polypeptide.

### Claim 5 (depends on 4)

The defined culture medium of claim 4, further comprising a stabilizing agent of said WNT3A, with the proviso that said stabilizing agent is not a lipid vesicle.

### Claim 6 (depends on 1)

The defined culture medium of claim 1, with the proviso that the medium does not comprise more than 0.009 μM of an ERK1/2 inhibitor.

### Claim 7 (depends on 3)

The defined culture medium of claim 3, wherein said GSK3β inhibitor is CHIR99021.

### Claim 8 (depends on 1)

The defined culture medium of claim 1, further comprising leukemia inhibitory factor (LIF).

### Claim 9 (depends on 1)

The defined culture medium of claim 1, further comprising the IL6RIL6 chimera.

### Claim 10 (depends on 1)

The defined culture medium of claim 1, being devoid of a JNK inhibitor.

### Claim 11 (depends on 1)

The defined culture medium of claim 1, being devoid of a p38 inhibitor.

### Claim 12 (depends on 1)

The defined culture medium of claim 1, wherein said culture medium does not comprise more than 1 ng/ml of basic fibroblast growth factor (bFGF).

### Claim 13 (depends on 1)

The defined culture medium of claim 1, being devoid of basic fibroblast growth factor (bFGF).

### Claim 14 (depends on 1)

The defined culture medium of claim 1, being capable of maintaining pluripotent stem cells in a pluripotent state for at least 5 passages when cultured in a suspension culture devoid of substrate adherence.

### Claim 15 (depends on 1)

A method of culturing pluripotent stem cells in a suspension culture devoid of substrate adherence, comprising culturing the pluripotent stem cells in the defined culture medium of claim 1, thereby culturing the pluripotent stem cells in the suspension culture.

### Claim 16 (depends on 15)

The method of claim 15, wherein said culture medium is capable of maintaining said pluripotent stem cells in a pluripotent state for at least 5 passages when cultured in a suspension culture devoid of substrate adherence.

### Claim 17 (depends on 15)

The method of claim 15, for expanding said pluripotent stem cells while maintaining said pluripotent stem cells in a proliferative, pluripotent and undifferentiated state.

### Claim 18 (depends on 15)

The method of claim 15, wherein said pluripotent stem cells are induced pluripotent stem cells.

### Claim 19 (depends on 15)

The method of claim 15, wherein said pluripotent stem cells are embryonic stem cells.

### Claim 20 (depends on 15)

The method of claim 15, wherein said pluripotent stem cells are human pluripotent stem cells.
